Editorial |

Lyme Disease Serology:  Problems and Opportunities

Gary P. Wormser, MD; Maria E. Aguero-Rosenfeld, MD; Robert B. Nadelman, MD
JAMA. 1999;282(1):79-80. doi:10.1001/jama.282.1.79.
Text Size: A A A
Published online


Serologic assays for Lyme disease, first used in 1983,1 are widely ordered in the United States, with an estimated 2.8 million tests performed annually.2 High demand undoubtedly has provided a potent stimulus for the development and marketing of a large number of assays for detection of antibody to Borrelia burgdorferi. As reported by Brown and colleagues3 of the Food and Drug Administration (FDA) in this issue of THE JOURNAL, 45 first-step assays, including enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays (IFAs), or immunodot techniques, and 8 second-step (supplemental) immunoblot assays have been granted FDA approval. Given the tremendous interest in these tests, it is important for physicians, other health care professionals, and the public to appreciate the strengths and limitations of these tests so that they are used in a helpful way. Brown and colleagues have addressed many of these issues in their article.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 20

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

The Rational Clinical Examination
Make the Diagnosis: Erythema Migrans

The Rational Clinical Examination
Original Article: Does This Patient Have Erythema Migrans?